III期和IV期淋巴肉瘤和网状细胞肉瘤放化疗联合（或不联合）主动免疫治疗的初步结果：结果与世界卫生组织分类的相关性

Preliminary results of chemoradiotherapy followed (or not ) by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma: correlation of the results with WHO categorization.

作者信息

Misset J L, Mathé G, Tubiana M, Caillou B, de Vassal F, Pouillart P, Gil M, Tentas C, Hayat M, Schwarzenberg L, Jasmin C, Delgado M, Machover D, Ribaud P, Musset M

出版信息

Recent Results Cancer Res. 1978;65:188-96. doi: 10.1007/978-3-642-81249-1_23.

DOI:10.1007/978-3-642-81249-1_23

PMID:370939

Abstract

One hundred and one patients with advanced (stage III and IV) LS and RS at the first presentation of the disease or on relapse were treated with a regimen combining initial chemotherapy, complementary radiotherapy on "icebergs," supplementary chemotherapy, and finally, active immunotherapy. The overall complete remission rate was about 79% for LS and 73% for RS. About 50% of the patients were still in remission for both diseases after 2 years; 60% with LS were still alive after 2 years and 44% with Rs. This study shows the useful prognostic value of the WHO classification for LS and RS: the prognosis of prolymphocytic (centrofollicular) LS is far better than that of the lymphoblastic type, which is itself better than that of the very poor prognostic immunoblastic type. The prognosis of RS is intermediate between that of the best prognostic type and that of the poorest prognostic type of LS.

摘要

101例初诊或复发时处于晚期（III期和IV期）的大颗粒淋巴细胞白血病（LS）和小颗粒淋巴细胞白血病（RS）患者接受了一种联合治疗方案，包括初始化疗、针对“冰山”的辅助放疗、补充化疗，最后是主动免疫治疗。LS的总体完全缓解率约为79%，RS为73%。约50%的患者在2年后两种疾病仍处于缓解状态；2年后，60%的LS患者仍存活，RS患者为44%。本研究显示了世界卫生组织（WHO）分类对LS和RS的有用预后价值：前淋巴细胞（中心滤泡性）LS的预后远优于淋巴细胞母细胞型，而淋巴细胞母细胞型本身又优于预后极差的免疫母细胞型。RS的预后介于LS最佳预后类型和最差预后类型之间。